The conversion from accelerated approval to traditional approval was supported by data from the phase 3 KEYNOTE-811 trial.

Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will ...

With rain starting to pour heavily, the Okanogan coach called the match early, granting wins to those who had already ...

Lead Author Abstract Title Presentation Details Pro. Jie Hu 67P - A Phase II Study of SunvozertinibCombined with Anlotinib in ...

The US Food and Drug Administration (FDA) has granted traditional approval to Merck & Co’s (NYSE: MRK) Keytruda ...

A  team of researchers from Cleveland Clinic share insights from an early set of 19,000 patients to receive immune checkpoint inhibitor treatments for colorectal cancer in the US.   The report comes ...

The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.

Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for HLX22, the company's innovative anti-HER2 monoclonal ...

The report delivers a comprehensive analysis of global biologics sales. Covering cancer antibodies, non-TNF inflammatory mAbs, biosimilars, gene therapy, RNA-based drugs, and more, the report provides ...

Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ('CSPC') (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...

Astellas Pharma’s strong pipeline and revenue growth support a positive outlook. See why ALPMF stock is a "Buy," driven by ...